SeekingAlphaOctober 7, 2026 at 2:05 AM NY20 Days Ago
Celldex Therapeutics: Trying To Put Its Troubled History Behind It
Celldex's recent Phase 3 barzolvolimab trials in chronic spontaneous urticaria met endpoints, but the market reaction was negative. Read more on CLDX stock here.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: SeekingAlpha
